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he RanGTPase activating protein RanGAP1 has essen-
tial functions in both nucleocytoplasmic transport and
mitosis. In interphase, a signiﬁcant fraction of vertebrate
SUMO1-modiﬁed RanGAP1 forms a stable complex with
the nucleoporin RanBP2/Nup358 at nuclear pore complexes.
RanBP2 not only acts in the RanGTPase cycle but also is a
SUMO1 E3 ligase. Here, we show that RanGAP1 is phosphor-
ylated on residues T409, S428, and S442. Phosphorylation
occurs before nuclear envelope breakdown and is maintained
T
 
throughout mitosis. Nocodazole arrest leads to quantita-
tive phosphorylation. The M-phase kinase cyclin B/Cdk1
phosphorylates RanGAP1 efﬁciently in vitro, and T409
phosphorylation correlates with nuclear accumulation of
cyclin B1 in vivo. We ﬁnd that phosphorylated RanGAP1
remains associated with RanBP2/Nup358 and the SUMO
E2–conjugating enzyme Ubc9 in mitosis, hence mitotic
phosphorylation may have functional consequences for the
RanGTPase cycle and/or for RanBP2-dependent sumoylation.
 
Introduction
 
The GTPase Ran serves essential roles in nucleocytoplasmic
transport, mitotic spindle formation, checkpoint control,
and postmitotic nuclear envelope reassembly (Arnaoutov
and Dasso, 2003; Quimby and Dasso, 2003; Walther et al.,
2003). These functions are accomplished in part by the
asymmetric localization of the RanGTPase activating pro-
tein RanGAP1 and the guanine-nucleotide exchange factor
RCC1. RCC1 is dynamically chromatin associated in inter-
phase and mitosis (Li et al., 2003). RanGAP1 is cytoplasmic
in interphase cells, with a large fraction stably associated
with the nucleoporin RanBP2/Nup358 at the cytoplasmic
face of the nuclear pore complex (NPC). This interaction
requires modification of RanGAP1 with the ubiquitin-
related protein SUMO1 (Matunis et al., 1996; Mahajan et
al., 1997). Interestingly, RanBP2 serves both as a docking
factor in transport and as an E3 ligase for sumoylation
(Pichler et al., 2002). In mitosis, RanGAP1 and RanBP2 are
diffusely distributed throughout the cell, albeit a small
fraction of both proteins is also observed at the mitotic
spindle and at kinetochores (Matunis et al., 1996; Joseph
et al., 2002).
To accommodate Ran’s different functions in interphase
and mitosis, components of the RanGTPase cycle are likely
to be cell cycle regulated. A first example is the RanGTP
interacting protein RanBP1, whose levels increase from S-phase
to metaphase and decline during late telophase (Guarguaglini
et al., 2000). RanBP2 is hyperphosphorylated during mito-
sis, but the consequences of this are unknown (Favreau et
al., 1996). Here, we show that RanGAP1 is subject to mi-
totic phosphorylation at three closely spaced residues in its
COOH-terminal domain. Phosphorylation occurs at the
NPC before nuclear envelope breakdown, but does not
disrupt the RanGAP1*SUMO1–RanBP2–Ubc9 interac-
tion. RanGAP1 phosphorylation may potentially alter Ran-
GAP1’s catalytic activity or RanBP2-mediated sumoylation
in vivo.
 
Results and discussion
 
RanGAP1 is phosphorylated during mitosis
 
To investigate whether or not RanGAP1 undergoes cell
cycle–dependent changes, we synchronized HeLa cells in
early S-phase and took samples as cells progressed through
the cell cycle. Immunoblotting revealed that RanGAP1
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abundance and sumoylation level remained unchanged (Fig.
1 A). However, two species of SUMO1-modified RanGAP1
with lower mobility (Fig. 1 A, bands a and b) were first visi-
ble at a time coincident with the onset of mitosis (9 h after
release). Maximal levels of these species were observed at 10
h after release, at which time the mitotic index was highest
(34%). Cyclin A and B1 protein levels had already declined,
indicating that the majority of cells had progressed through
the metaphase–anaphase transition at this point. Nocoda-
zole arrest led to quantitative conversion of sumoylated
RanGAP1 into the species designated band a (Fig. 1 A).
Phosphatase treatment demonstrated that bands a and b rep-
resent phosphorylated RanGAP1 (unpublished data).
 
Identification of three phosphorylation sites in RanGAP1
 
Mass spectrometry was used to identify the phosphorylated
residues in RanGAP1 (Fig. 2). For this process, species repre-
sented by bands a, b, and c were enriched by immunoprecip-
itation from nocodazole and interphase lysates (Fig. 2 A).
Bands a and c were obtained from digitonin-lysates, band b
was obtained from hypotonic swelling lysates (for unknown
reasons, band a was rapidly converted to band b during hy-
potonic swelling). Coomassie-stained bands a, b, and c
were subjected to in-gel digestion by trypsin and analyzed
by matrix-assisted laser desorption/ionization time-of-flight
(MALDI-TOF) mass spectrometry (Fig. 2 B). A peptide
(amino acids 407–445 in human RanGAP1) containing up
to three phosphates was identified; only the unphosphory-
lated species was obtained from band c, up to two phosphates
were detected in the peptide from band b, and two or three
phosphates were present in the peptide from band a. From
this analysis, we concluded that the two RanGAP1 phospho-
forms a and b were phosphorylated at three and two residues,
respectively. The two phosphorylated residues in band b were
unequivocally identified as Ser 428 and Ser 442 through se-
quencing of the doubly phosphorylated peptide 414–445 by
electrospray ionization ion trap mass spectrometry (Fig. 2 C).
Identification of the three sites in band a failed with this
method. We considered it likely that band a was also phos-
phorylated at Ser 428 and Ser 442. A good candidate for the
third residue was Thr 409, as it is part of a consensus motif
for Cdks (TPSRK). To test if Thr 409 was phosphorylated
in vivo, and to confirm phosphorylation at the other sites,
we generated three phosphospecific antibodies directed to-
ward p-T409, p-S428, and p-S442. These antibodies were
used to probe RanGAP1 immunoprecipitated from inter-
phase and nocodazole extracts (Fig. 2 D). Indeed, mitotic
phosphorylation of RanGAP1 occurs at T409, S428 and
S442. Band a is phosphorylated at all three residues, whereas
band b is only phosphorylated at S428 and S442.
 
Phosphorylation of RanGAP1 occurs before nuclear 
envelope breakdown
 
Next, we tested the phosphospecific antibodies in immuno-
fluorescence. 
 
 
 
 p-T409 strongly decorates cells from pro-
phase to telophase. Fig. 3 A shows representative images for
different mitotic stages. In metaphase and anaphase, strong
cytoplasmic staining and some enhancement at the mitotic
spindle was visible, consistent with previous reports on
RanGAP1 localization in mitosis (Matunis et al., 1996; Jo-
seph et al., 2002). 
 
 
 
 P-S428 and 
 
 
 
 P-S442 antibodies are
weaker and appear to give rise to more background, but they
also clearly decorate mitotic cells (Fig. 3 B). Interestingly,
relative intensities of signals between prophase and telophase
varied for the three antibodies, suggesting differential timing
of phosphorylation or dephosphorylation. To address this is-
sue, we immunoprecipitated RanGAP1 from cells at dif-
ferent time points after thymidine release and detected
RanGAP1 by immunoblotting with the phosphospecific an-
tibodies (Fig. 3 C). At 9 h after release, band a is already
Figure 1. Cell cycle–dependent phos-
phorylation of RanGAP1. (A) HeLa cells 
arrested in S-phase with thymidine were 
released from the S-phase block, harvested 
at the indicated times, and analyzed 
by immunoblotting with antibodies to 
RanGAP1, cyclin A, and cyclin B. For 
optimal resolution of RanGAP1 species 
a, b, and c, 6% SDS-PAGE was used for 
the top panel. Note that all time points 
were run on the same gel. (B) Mitotic 
index was determined by visually scoring 
fixed cells stained with Hoechst for the 
presence of condensed chromosomes. 
About 200 cells were scored at each 
time point. (C) Cell cycle analysis: DNA 
content of each sample was determined 
by propidium iodine staining and analysis 
by flow cytometry. 
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present, whereas little singly phosphorylated S442 (comi-
grating with unphosphorylated RanGAP1) and no singly
phosphorylated T409 or S428 is detectable. This finding
suggests that RanGAP1 is initially phosphorylated at all
three sites. In contrast, dephosphorylation appears sequen-
tial, as p-T409 clearly disappears before the other two phos-
phorylated sites. Together, we find that RanGAP1 is phos-
phorylated at the onset of mitosis before nuclear envelope
breakdown. Differential timing of dephosphorylation of the
three sites in RanGAP1 results in at least three distinct mi-
totic RanGAP1 species: a triply phosphorylated species, and
two species phosphorylated at both S428 and S442 or only
at S442.
 
Cdks phosphorylate RanGAP1
 
Threonine 409 and serine 442 in human RanGAP1
(T411 and S444 in murine RanGAP1; Fig. 2 E) lie within
consensus motifs for Cdks (T/S-P-X-K/R; Kreegipuu et
al., 1999). Therefore, we tested whether or not Cdks
present in nocodazole extracts contribute to RanGAP1
phosphorylation. In vitro sumoylated RanGAP1 was incu-
bated with nocodazole extracts in the presence or absence
of the Cdk-specific inhibitor p27 (Hengst and Reed,
1998). Indeed, incubation with p27 prevented the appear-
ance of a higher molecular weight form (Fig. 4 A), indi-
cating that Cdk activity was indeed required for Ran-
GAP1 phosphorylation. Next, we demonstrated efficient
in vitro phosphorylation of RanGAP1 with two recombi-
nant Cdks, cyclin A/Cdk2 and cyclin B/Cdk1(Fig. 4 B).
Mutagenesis of Thr 411, but not of Ser 444, severely re-
duced phosphorylation by either kinase, and phosphory-
lation was completely abolished in the double mutant
T411D, S444D (Fig. 4 B). These data demonstrate that
recombinant cyclin A/Cdk2 and cyclin B/Cdk1 phosphor-
ylate mouse RanGAP1 in vitro, with a strong preference
for Thr 411. Considering the timing and location of
RanGAP1 phosphorylation, Cdk1, but not the G1/S ki-
nase Cdk2, is a likely candidate in vivo. Three major
Cdk1 kinases contribute to mitosis, cyclin A/Cdk1, cyclin
B1/Cdk1, and cyclin B2/Cdk1. Of these, cyclin B1/Cdk1
is the most obvious candidate. Cyclin B1, which is already
expressed in the G2 phase of the cell cycle, forms a com-
plex with inactive Cdk1 and is localized in the cytoplasm.
At the onset of mitosis, cyclin B1/Cdk1 rapidly accumu-
lates in the nucleus (Yang and Kornbluth, 1999; Takizawa
and Morgan, 2000; Toyoshima-Morimoto et al., 2001).
Double labeling with 
 
 
 
 cyclin B1 and 
 
 
 
 p-T409 antibod-
ies (Fig. 4 C) demonstrated that strong nuclear envelope
Figure 2. Mitotic RanGAP1 is phosphorylated at residues T409, S428, and S442 in vivo. (A) RanGAP1 species required for mass spectrometry 
(indicated as bands a, b, and c) were enriched by immunoprecipitation from HeLa cell extracts. A fraction of the precipitates was subjected to 
immunoblotting with  -RanGAP1 antibodies. The remainder was separated on SDS-PAGE (not depicted), and Coomassie-stained bands a, b, 
and c were excised from lanes 2, 3, and 1, respectively. cyc, cycling cells; nocodazole, nocodazole-arrested cells; dig, digitonin lysis; hyp, 
hypotonic swelling extracts. (B) MALDI-TOF mass spectra of a tryptic digest of RanGAP1 species enriched as described in A. Top, band c; 
middle, band a; bottom, band b. A peptide (amino acids 407–445 in human RanGAP1) containing up to three phosphates was identified. 
A selected mass range containing different phosphorylation stages (0, 1, 2, and 3 Ph) of this peptide is depicted. (C) Scheme showing the 
localization of two phosphorylation sites through fragmentation of the doubly phosphorylated peptide (amino acids 414–445) of RanGAP1 
using an electrospray ionization ion trap mass spectrometer. The number of phosphorylation sites that were observed on each fragment is 
added as an arabic number to the arrows. (D) RanGAP1 immunoprecipitated with   RanGAP1 antibodies from cycling and nocodazole-
arrested HeLa cells was analyzed by immunoblotting with the indicated phosphospecific antibodies. (E) All three phosphorylation sites of 
human RanGAP1 are conserved in mouse, areas surrounding S442 and S428 are also conserved in Xenopus laevis RanGAP1. 
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labeling was first seen in prophase cells with intranuclear
cyclin B1 and condensed chromatin (Fig. 4 C). Collec-
tively, these findings make cyclin B1/Cdk1 the best candi-
date for phosphorylating T409.
 
RanGAP1 phosphorylation does not disrupt interactions 
with RanBP2 and Ubc9
 
Mitotic phosphorylation by cyclin B/Cdk1 has been sug-
gested to facilitate disassembly and, potentially, reassembly
Figure 3. RanGAP1 phosphorylation takes place before nuclear envelope breakdown. (A) HeLa cells fixed and permeabilized with 4% PFA 
and 0.2% Triton X-100 were subjected to indirect immunofluorescence with   p-T409 antibody. (B) HeLa cells were fixed with 2% PFA, 
permeabilized with 0.2% Triton X-100, and stained with primary antibodies as indicated. (C) At least three distinct phosphorylated RanGAP1 
species exist during mitosis. (lanes 2–7)   RanGAP1 immunoprecipitates from cells harvested at indicated times after release from thymidine 
(same cells as in Fig. 1). (lanes 1, 8, and 9) Total extracts from cycling (cyc) and nocodazole (noc) extracts served as controls. Immunoblotting 
was done with the indicated phosphospecific antibodies.
Figure 4. RanGAP1 phosphorylation by 
Cdks. (A) Phosphorylation of RanGAP1 
in HeLa cell extracts is inhibited by p27. 
Recombinant sumoylated RanGAP1 was 
incubated with nocodazole extracts in 
the presence of ATP and analyzed by 
immunoblotting with   RanGAP1. 
Phosphorylation results in a mobility 
shift (arrows). Where indicated, extracts 
were preincubated with p27 before 
RanGAP1*SUMO1 addition. (B) In vitro 
phosphorylation of recombinant RanGAP1 
with cyclin A/Cdk2 or cyclin B/Cdk1. 
After incubation, samples were analyzed 
by SDS-PAGE and autoradiography. p27 
was included to demonstrate specificity of 
the kinase preparations. Mouse RanGAP1 
mutants: T-D, RanGAP1-T411D; S-D, 
RanGAP1-S444D; DD, RanGAP1-T411D, 
S444D. (C) In vivo phosphorylation of 
human RanGAP1 T409 correlates with 
levels and localization of cyclin B. HeLa 
cells fixed with 2% PFA and permeabilized 
with 0.2% Triton X-100 were stained 
with   p-T409 antibodies and   cyclin B. 
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of NPCs (Macaulay et al., 1995; Favreau et al., 1996).
RanGAP1 phosphorylation at the G2–M transition takes
place at residues directly adjacent to and within the domain
required for interaction with RanBP2 (amino acids 420–470
in mouse RanGAP1; Matunis et al., 1998). Therefore, it was
possible that phosphorylation disrupts this interaction as
part of the NPC disassembly process. However, as shown in
Fig. 5 A (top), phosphorylated RanGAP1 coimmunoprecip-
itated with RanBP2 from RIPA buffer extracts, indicating
that the RanGAP1*SUMO1–RanBP2 complex is main-
tained stably in mitosis. It has previously been shown that a
small fraction of the SUMO E2 enzyme Ubc9 is associated
with the RanGAP1*SUMO1–RanBP2 complex at the NPC
in interphase (Zhang et al., 2002). As shown in Fig. 5 A, Ubc9
also coimmunoprecipates with RanGAP1 and RanBP2 from
mitotic extracts (bottom).
 
Possible functions of RanGAP1 phosphorylation
 
We find that sumoylated RanGAP1 remains associated
with RanBP2 and Ubc9 in mitosis, irrespective of its
phosphorylation state. This complex regulates two differ-
ent processes, the RanGTPase cycle and sumoylation of
specific targets (Fig. 5 B). Therefore, two distinct func-
tions for RanGAP1 phosphorylation can be envisaged.
RanGAP1 phosphorylation may modulate RanGAP1’s
catalytic activity. This modulation would have to involve
recruitment of an unknown binding partner, as a direct
effect of phosphorylation on the catalytic activity was not
detected (Fig. S1, available at http://www.jcb.org/cgi/
content/full/jcb.200309126/DC1). Alternatively, phos-
phorylated RanGAP1 may recruit specific SUMO target
proteins to RanBP2’s catalytic domain. Interestingly,
RanBP2 has recently been found to be essential for kinet-
ochore function in mitosis (Salina et al., 2003). Although
it is not known if RanBP2 targets RanGAP1 to kineto-
chores (Joseph et al., 2002; Arnaoutov and Dasso, 2003),
or if the E3 ligase activity is required at this site, sumoy-
lation does have an important role in chromosome
segregation (for review see Seeler and Dejean, 2003).
Identification of binding partners for the mitotic Ran-
GAP1*SUMO1–RanBP2 complex will aid in distinguish-
ing between these predicted functions.
 
Materials and methods
 
Plasmids and recombinant proteins
 
The expression plasmid for mouse RanGAP1 was as described by Mahajan
et al. (1997). Mutants of RanGAP1 were engineered by site-directed mu-
tagenesis. Purification of recombinant RanGAP1 followed published pro-
cedures (Mahajan et al., 1997). In vitro sumoylation of RanGAP1 with
Aos1/Uba2 and Ubc9 was as described by Pichler et al. (2002). Bacterially
expressed p27 and cyclin A/Cdk2 expressed in baculovirus were prepared
as described previously (Hengst et al., 1998; Hengst and Reed, 1996). Cy-
clin B/Cdk1 was purchased from Calbiochem.
 
Antibodies
 
Goat 
 
 
 
-RanGAP1, goat 
 
 
 
-Ubc9, rabbit 
 
 
 
-RanBP2 (Pichler et al., 2002),
and rabbit 
 
 
 
–cyclin A antibodies were described previously (Hengst and
Reed, 1996). For phosphospecific antibodies, the following peptides were
coupled to ovalbumin: T409, CEKSApTPSRKI; S428, CPVLSpSPPPAD; and
S442, CAFPpSPEKLLR. Initial injection into goats was as an emulsion with
Titermax Gold (Sigma-Aldrich), booster injections were with Freund’s in-
complete adjuvant. Antibodies were affinity purified on phosphopeptides
coupled to EAH-Sepharose 6B (Amersham Biosciences), eluted with 0.2 M
acetic acid, pH 2.7, and 0.5 M NaCl, and dialyzed against PBS. Before
use, antibodies were preadsorbed against immobilized nonphosphorylated
peptides. Mouse 
 
 
 
–cyclin B and rabbit 
 
 
 
-GFP antibodies were obtained
from Santa Cruz Biotechnology, Inc. Alexa 488 donkey 
 
 
 
 goat was pur-
chased from Molecular Probes, other secondary antibodies were pur-
chased from Jackson ImmunoResearch Laboratories.
 
Immunoblotting and fluorescence microscopy
 
Detection of antigens on nitrocellulose was performed with affinity-puri-
fied goat 
 
 
 
 p-T409 (0.5 
 
 
 
g/ml), 
 
 
 
 p-S428 (0.4 
 
 
 
g/ml), 
 
 
 
 p-S442 (0.7 
 
 
 
g/
ml), or 
 
 
 
 RanGAP1 (0.25 
 
 
 
g/ml) in 5% milk powder (or 0.2% gelatine) in
PBS, 0.2% Tween 20 for 1 h at RT. Detection was performed by chemilu-
minescence. For indirect immunofluorescence, adherent HeLa cells
grown on coverslips were either fixed for 10 min with 2% PFA in PBS, 1
mM MgCl
 
2
 
, and permeabilized for 5 min with 0.2% Triton X-100 in PBS,
1 mM MgCl
 
2
 
, or permeabilized and fixed for 10 min in 4% PFA, 0.2%
Triton X-100, 20 mM PIPES, 1 mM MgCl
 
2
 
, and 10 mM EGTA (Kapoor et
al., 2000). Antibodies in 2% BSA, PBS/MgCl
 
2
 
 were used at 0.25 
 
 
 
g/ml
Figure 5. RanGAP1*SUMO1 phosphoforms a and 
b remain associated with RanBP2 and Ubc9 in 
nocodazole-arrested HeLa cells. (A)   RanGAP1 and 
  RanBP2 immunoprecipitates from cycling and 
nocodazole-arrested cells (RIPA extracts) were analyzed 
for the presence of RanGAP1 (top) and Ubc9 (bottom) 
by immunoblotting. IgGs 1 and 2 were from the 
respective preimmune sera and served as specificity 
controls. (B) Model: the RanGAP1*SUMO1–RanBP2 
complex serves a dual function as an activator of 
Ran-GTP hydrolysis and as a SUMO E3 ligase. Either 
process may be affected by mitotic phosphorylation 
of RanGAP1. 
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-RanGAP1), 1 
 
 
 
g/ml (
 
 
 
 p-T409 and 
 
 
 
 p-S428), and 2 
 
 
 
g/ml (
 
 
 
 p-S442),
and at 1:100 (
 
 
 
 cyclin B). Alexa 488 donkey 
 
 
 
 goat and Cy3 donkey 
 
 
 
mouse antibodies were at 1:500. Hoechst 33342 was included with the
secondary antibodies at 0.2 
 
 
 
g/ml. Pictures of cells mounted in ProLong
Antifade (Molecular Probes) were taken with a microscope (model Ax-
ioskop II; Carl Zeiss MicroImaging, Inc.), 63
 
 
 
 Plan Apochromat lens (ap-
erture 1.4, oil), using a camera (model MicroMax CCD; Princeton Instru-
ments) and Iplab software.
 
Immunoprecipitations
 
Immunoprecipitations were from SDS-lysates, digitonin cytosol, cytosol
generated by hypotonic swelling, or from RIPA extracts from cycling and
nocodazole-arrested HeLa cells. For SDS-lysate, HeLa suspension cells
were lysed by boiling in 1% SDS and diluted 10-fold with RIPA buffer-SDS
(50 mM Tris-HCl, pH 8, 150 mM NaCl, 1% NP-40, 0.5% deoxycholate, 1
mM DTT, and 1 
 
 
 
g/ml pepstatin, aprotinin, and leupeptin). Hypotonic
swelling extracts were generated as described previously (Melchior, 1998),
and buffer was changed to TB buffer with protease inhibitors and phos-
phatase inhibitor cocktail I (Sigma-Aldrich) using PD10 columns (Amer-
sham Biosciences). For digitonin cytosol, HeLa cells were lysed in TB con-
taining protease inhibitors and phosphatase inhibitor cocktail I and
0.005% digitonin (Calbiochem). For RIPA extracts, HeLa suspension cells
were lysed by sonification in 4 vol RIPA buffer with protease inhibitors,
phosphatase inhibitor cocktail I, and 10 mM iodoacetamide. All cell ly-
sates were clarified at 100,000 
 
g
 
 for 45 min before use in IP. Affinity-puri-
fied antibodies or control IgGs cross-linked at 2 mg/ml to Ultralink Immo-
bilized Protein G Plus beads (Pierce Chemical Co.) were incubated with
extracts for 90 min at 4
 
 
 
C. Beads were washed three times in RIPA buffer
and boiled in SDS-Laemmli loading buffer.
 
Cell cycle analysis of RanGAP1 phosphorylation
 
A standard double thymidine block release protocol was used to obtain a
synchronous population of suspension HeLa cells (Bonifacino et al., 1999).
At indicated times, cells were harvested by centrifugation, aliquots flash
frozen, and stored at 
 
 
 
80
 
 
 
C. Aliquots were used for analysis by immuno-
blotting upon lysis in Laemmli buffer or for immunoprecipitation upon
SDS-lysis. Progression through the cell cycle was monitored by FACS
 
®
 
analysis after cell fixation in 70% ethanol and staining with propidium io-
dide (Bonifacino et al., 1999). To determine the mitotic index, cells were
fixed in 70% ethanol, stained using a final concentration of 4 ng/
 
 
 
l
Hoechst 33342 (Molecular Probes), mounted with Glow mounting me-
dium (EnerGene), and observed using a microscope (model Axioskop II;
Carl Zeiss MicroImaging, Inc.).
 
In vitro RanGAP1 phosphorylation
 
Phosphorylation of 2 
 
 
 
g RanGAP1 with recombinant kinases was in 20
mM Tris-HCl, pH 7.5, 10 mM MgCl
 
2
 
, 50 
 
 
 
M ATP, and 10 
 
 
 
Ci 
 
 
 
[
 
32
 
P]ATP
at 30
 
 
 
C for 30 min. Cyclin B/Cdk1 (Calbiochem) and cyclin A/Cdk2 were
used at 2 U or 5 ng, respectively. Analysis was performed by SDS-PAGE
and autoradiography. Mitotic extracts for RanGAP1 phosphorylation were
prepared from 100 ml of nocodazole-arrested HeLa cells by freeze-thaw
lysis in 1.5 ml TB buffer supplemented with phosphatase inhibitor cocktail
I. 100 ng of SUMO1-modified RanGAP1 was incubated in 5 
 
 
 
l of extracts
and 1 mM of ATP at 30
 
 
 
C for 2 h. Recombinant p27 at concentrations of 1
 
 
 
g or 5 
 
 
 
g was used to pretreat mitotic cell extracts on ice for 45 min. Re-
actions were analyzed by immunoblotting with 
 
 
 
 RanGAP1 antibodies.
 
Mass spectrometry
 
Coomassie-stained protein bands were in-gel digested by trypsin (sequenc-
ing grade; Promega) using essentially the protocol of Shevchenko et al.
(1996) and desalted using home-made miniaturized reversed-phase col-
umns (Gobom et al., 1999). MALDI-TOF mass spectra were acquired on a
Reflex III instrument (Bruker Daltonik) in positive ion reflector mode. As a
matrix, 2,5 dihydroxybenzoic acid (Bruker Daltonik) was used. For peptide
sequence analysis by electrospray tandem mass spectrometry, samples
were filled into nano electrospray needles (Protana) and analyzed on an
ion trap (model Esquire 3000
 
 
 
; Bruker Daltonik) mass spectrometer.
 
Online supplemental material
 
GAP assays were performed as described previously (Mahajan et al., 1997)
using 
 
 
 
-[
 
32
 
P]Ran-GTP and immunoprecipitated or using recombinant
RanGAP1. Analysis was performed by TLC. Amounts of GTP and GDP were
determined using a PhosphorImager (model BAS-2500, Fuji FILM). Online
supplemental material is available at http://www.jcb.org/cgi/content/full/
jcb.200309126/DC1.
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